Scholarlink

Objectives <p>Endometriosis-related dysmenorrhea and pelvic pain impose significant economic and quality-of-life burdens. This study evaluated the cost-effectiveness of dienogest compared to gonadotropin-releasing hormone agonists (GnRH-a) for managing dysmenorrhea and pelvic pain in Vietnam.</p> Design <p>The cost-effectiveness analysis using a Markov model was conducted from a healthcare payer perspective. Model input parameters were obtained from meta-analyses, published literature, and local data sources. One-way sensitivity, and probabilistic sensitivity analyses (PSA) were performed to assess the robustness of the findings.</p> Setting <p>Vietnamese healthcare system context.</p> Participants <p>Hypothetical cohort of women with endometriosis experiencing dysmenorrhea or pelvic pain.</p> Interventions <p>Dienogest compared with GnRH-a therapies (triptorelin, leuprorelin, goserelin).</p> Main outcome measures <p>Costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calculated over two years.</p> Results <p>Dienogest was the dominant treatment for dysmenorrhea, with the lowest cost ($363.3) and highest QALYs (1.74) compared to triptorelin ($739.3; 1.62 QALYs; ICER −$3,292/QALY) and leuprorelin ($744.0; 1.70 QALYs; ICER −$11,454/QALY). For pelvic pain, dienogest ($381.5, 1.64 QALYs) also dominated triptorelin ($720.4; 1.60 QALYs; ICER −$10,919/QALY), leuprorelin ($773.4; 1.54 QALYs; ICER −$4,300/QALY), and goserelin ($753.1; 1.49 QALYs; ICER −$2,609/QALY).One-way sensitivity analysis identified the probability of symptom resolution and utility values as key drivers of cost-effectiveness. PSA confirmed dienogest’s high probability (≥ 99%) of being cost-effective at a willingness-to-pay threshold of one GDP per capita.</p> Conclusion <p>Dienogest is a cost-effective alternative to GnRH-a drugs for treating dysmenorrhea and pelvic pain in Vietnam, offering improved health outcomes at a lower cost. These findings support its broader adoption in clinical practice and healthcare policy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cost-effectiveness of dienogest compared to gonadotropin releasing hormone agonists for the management of endometriosis in Vietnam

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月29日

查看全文
  • Mai Thi Tuyet Kieu,
  • Minh Hong Le,
  • Chi Phuong Nguyen

摘要

Objectives

Endometriosis-related dysmenorrhea and pelvic pain impose significant economic and quality-of-life burdens. This study evaluated the cost-effectiveness of dienogest compared to gonadotropin-releasing hormone agonists (GnRH-a) for managing dysmenorrhea and pelvic pain in Vietnam.

Design

The cost-effectiveness analysis using a Markov model was conducted from a healthcare payer perspective. Model input parameters were obtained from meta-analyses, published literature, and local data sources. One-way sensitivity, and probabilistic sensitivity analyses (PSA) were performed to assess the robustness of the findings.

Setting

Vietnamese healthcare system context.

Participants

Hypothetical cohort of women with endometriosis experiencing dysmenorrhea or pelvic pain.

Interventions

Dienogest compared with GnRH-a therapies (triptorelin, leuprorelin, goserelin).

Main outcome measures

Costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calculated over two years.

Results

Dienogest was the dominant treatment for dysmenorrhea, with the lowest cost ($363.3) and highest QALYs (1.74) compared to triptorelin ($739.3; 1.62 QALYs; ICER −$3,292/QALY) and leuprorelin ($744.0; 1.70 QALYs; ICER −$11,454/QALY). For pelvic pain, dienogest ($381.5, 1.64 QALYs) also dominated triptorelin ($720.4; 1.60 QALYs; ICER −$10,919/QALY), leuprorelin ($773.4; 1.54 QALYs; ICER −$4,300/QALY), and goserelin ($753.1; 1.49 QALYs; ICER −$2,609/QALY).One-way sensitivity analysis identified the probability of symptom resolution and utility values as key drivers of cost-effectiveness. PSA confirmed dienogest’s high probability (≥ 99%) of being cost-effective at a willingness-to-pay threshold of one GDP per capita.

Conclusion

Dienogest is a cost-effective alternative to GnRH-a drugs for treating dysmenorrhea and pelvic pain in Vietnam, offering improved health outcomes at a lower cost. These findings support its broader adoption in clinical practice and healthcare policy.